{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/post-herpetic-neuralgia/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"f8c609d4-05b5-538c-b9c6-d643d7e7f5e8","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 398a4ff5-e703-40af-a99a-bfb558099503 --><h2>Changes</h2><!-- end field 398a4ff5-e703-40af-a99a-bfb558099503 -->","summary":null,"htmlStringContent":"<!-- begin item 3dc4fdfd-7edb-4681-81b8-c28fa7345c6c --><!-- begin field ae045020-1f4d-4d76-9427-e301671f2356 --><p><strong>July 2017 </strong>— minor update. Minor typographical corrections.</p><p><strong>February to March 2017 </strong>— reviewed. A literature search was conducted in February 2017 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of this topic. The topic has undergone restructuring. No major changes to the recommendations have been made.</p><!-- end field ae045020-1f4d-4d76-9427-e301671f2356 --><!-- end item 3dc4fdfd-7edb-4681-81b8-c28fa7345c6c -->","topic":{"id":"54614fe0-8a47-5df0-b8e9-67d6417eac0d","topicId":"42508b4e-7987-4ff7-9cd1-647315a678b7","topicName":"Post-herpetic neuralgia","slug":"post-herpetic-neuralgia","lastRevised":"Last revised in July 2017","chapters":[{"id":"b4e97191-f5f0-5efa-bc32-1a8739fb0524","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a657749a-6629-5da1-bf22-9d164969ca93","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"36c8e1f0-287e-5380-bc4f-f42ddf04e983","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f8c609d4-05b5-538c-b9c6-d643d7e7f5e8","slug":"changes","fullItemName":"Changes"},{"id":"92f79bd2-9e70-52dd-b404-510400482111","slug":"update","fullItemName":"Update"}]},{"id":"addbece3-3dce-55c5-83b0-bd2fdd225c1f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"a3192eb2-159a-5ddf-82bf-24a9364207ee","slug":"goals","fullItemName":"Goals"},{"id":"4f386102-bf02-582c-9139-eb6d81f97852","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"9b2dd798-4f3c-5194-a525-6fd005d0e2d3","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e4d6aaad-13cc-5127-b315-04879ba584e5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"6384851a-a5ee-56c3-ae26-accd5a02bda2","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f1189ae3-2db8-502c-aa1f-3de86bbd0aec","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"11d0f24e-273c-5602-a2a2-c1f9b6afb8fd","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e8bc827a-09c6-5d81-b648-e6aab18f479a","slug":"definition","fullItemName":"Definition"},{"id":"7d11ac85-acf6-5480-a72d-baaa197a6cd0","slug":"prevalence","fullItemName":"Prevalence"},{"id":"bcc711bf-9832-566c-86d0-a73e6f90ec7c","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"59f87b98-5214-5e7d-9f01-6ee75d527557","slug":"prognosis","fullItemName":"Prognosis"},{"id":"bbcea3ba-c2de-5140-8aa3-38794493bac7","slug":"complications","fullItemName":"Complications"}]},{"id":"d9de53aa-a485-59fd-890b-c2e883790326","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4106210e-2a16-5414-a10f-2e6f04295872","slug":"diagnosis","fullItemName":"Diagnosis"}]},{"id":"f6decb43-bacd-5d0d-bf99-39695913260e","fullItemName":"Management","slug":"management","subChapters":[{"id":"8de90f5c-0670-56d7-b5c7-dd38335fe889","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"6932895c-9dfd-5da5-a4dd-cba579bf4edd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"75ab84b5-9461-5828-a2ca-b50bf9f35cc0","slug":"neuropathic-pain-treatments","fullItemName":"Neuropathic pain treatments"},{"id":"e7ce9ec1-b3a2-5b78-a4e1-2e41055c4dcd","slug":"paracetamol-codeine","fullItemName":"Paracetamol and codeine"},{"id":"3b69fe1d-39be-5060-a4c5-001c53ce1c70","slug":"lidocaine-plasters","fullItemName":"Lidocaine plasters"}]},{"id":"53bc33fd-0728-532f-a15f-1caa6952c0f9","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"8aa7ebb2-f0d7-5611-9ea0-3ed478028b44","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"7e4288c2-3520-5856-bcd6-efe055368823","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c99e378c-55fa-5f4e-9bc3-33949142e857","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f1d65c20-04ce-5fa3-a7a4-dfc340714178","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"fd48516c-88c8-51e3-b7f9-231b96ff1bce","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"28d25826-2b2a-5f6f-822b-598bd4997c64","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0aa7c920-194e-5c04-ae6a-32f5ef3734ec","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"36c8e1f0-287e-5380-bc4f-f42ddf04e983","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"c57d0dcc-a7b1-5193-825f-73013c136dbb","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field 46f5c44e-8c2d-43c0-aed6-6565d63b9140 --><h3>Previous changes</h3><!-- end field 46f5c44e-8c2d-43c0-aed6-6565d63b9140 -->","summary":null,"htmlStringContent":"<!-- begin item b2e86ed0-aba8-451c-be71-2688c8ce5966 --><!-- begin field 1107914c-b3f4-46d0-9f17-a8894256e42b --><p><strong>March 2014 </strong>— minor update. With the exception of simple analgesics, the information on the pharmacological treatment of post-herpetic neuralgia has been removed and a link to the CKS topic on <em>Neuropathic Pain - Drug treatment</em> inserted. The referral node has been rewritten in line with the updated NICE guideline on the pharmacological treatment of neuropathic pain.</p><p><strong>October 2012 to March 2013 </strong>— reviewed. A literature search was conducted in September 2012 to identify evidence-based guidelines, UK policy, systematic reviews, and key RCTs published since the last revision of the topic. Changes to clinical recommendations have been made to reflect guidance on neuropathic pain published by the National Institute for Health and Care Excellence (NICE).</p><p><strong>August 2012 </strong>— minor update. Minor typographical error corrected.</p><p><strong>September 2010 </strong>— the choice of drug treatment for neuropathic pain has been updated in line with the NICE clinical guideline, <em>Neuropathic pain. The pharmacological management of neuropathic pain in adults in non-specialist settings</em>. Issued in September 2010.</p><p><strong>November 2009 </strong>— minor update to reflect that nonsteroidal anti-inflammatory drugs are not recommended because there is no evidence on their use in post-herpetic neuralgia. Issued in November 2009.</p><p><strong>March 2009 </strong>— minor update to include a link to the CKS topic on <em>Neuropathic Pain - Drug treatment</em>. Issued in April 2009.</p><p><strong>May to August 2008 </strong>— converted from CKS guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. This topic previously incorporated the management of shingles, for which a separate CKS topic is now available. There have been changes to the treatment recommendations.</p><p><strong>April 2008 </strong>— minor update. Update to the text in medicines management to reflect recent MHRA advice regarding genetic testing for carbamazepine. Issued May 2008.</p><p><strong>June 2007 </strong>— update. Gabapentin is now licensed up to a maximum dose of 3600 mg per day for the treatment of peripheral neuropathic pain. Issued in June 2007.</p><p><strong>October 2005 </strong>— minor technical update. Issued in November 2005.</p><p><strong>February 2005 </strong>— reviewed. Validated in June 2005 and issued in July 2005.</p><p><strong>December 2001</strong>— reviewed and guidance renamed <em>Shingles and postherpetic neuralgia </em>(previously called <em>Herpes zoster</em>). Validated in March 2002 and issued in April 2002.</p><p><strong>August 1998 </strong>— written.</p><!-- end field 1107914c-b3f4-46d0-9f17-a8894256e42b --><!-- end item b2e86ed0-aba8-451c-be71-2688c8ce5966 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}